Intravenous antidepressant treatment: focus on citalopram

@article{Kasper2002IntravenousAT,
  title={Intravenous antidepressant treatment: focus on citalopram},
  author={Siegfried Kasper and Franz M{\"u}ller-Spahn},
  journal={European Archives of Psychiatry and Clinical Neuroscience},
  year={2002},
  volume={252},
  pages={105-109}
}
During the last decade, the number of patients who consult primary care physicians or psychiatrists for symptoms of depression has doubled. The majority of depressed patients are prescribed oral medication; however, in several European countries antidepressant therapy may be initiated with a daily intravenous infusion. The choice of intravenous antidepressants was previously limited to agents such as dibenzepine, doxepin, clomipramine and viloxazine. More recently, the selective serotonin… 
Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration
TLDR
Both i.v. traZodone and clomipramine are rapid and effective options for improving depressive symptoms, although trazodone appears to be tolerated better.
Intravenous Augmentative Citalopram Versus Clomipramine in Partial/Nonresponder Depressed Patients: A Short-Term, Low Dose, Randomized, Placebo-Controlled Study
TLDR
It is suggested that both clomipramine and citalopram intravenous augmentation at low doses and for a short period are well tolerated and superior to placebo in major depressives with partial or no response to oral SSRIs with a possible superiority of citalsopram over clomIPramine with regard to anxiety-somatization symptoms.
Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study
TLDR
The present findings seem to suggest that short-term, low-dose, i.v. citalopram augmentation may be effective in depressed patients with partial or no response to oral SSRIs.
Safety and Efficacy of Oral Escitalopram as Continuation Treatment of Intravenous Citalopram in Patients with Major Depressive Disorder
TLDR
Escitalopram was well tolerated as a continuation treatment after switching from intravenous citaloprams and reduced depressive symptoms in patients with a moderate to severe major depressive episode.
Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers after Oral vs. Infusion Citalopram Therapy in Dextromethorphan- and Mephenytoin-Phenotyped Patients with Major Depression.
TLDR
Owing to CLT's high bioavailability, the plasma concentrations of its enantiomers remained largely independent on the administration route and no relationship was found between any cardiovascular parameters and pharmacokinetic and pharmacogenetic data.
Response to intravenous antidepressant treatment by suicidal vs. nonsuicidal depressed patients.
TLDR
Being suicidal may limit response to treatment in depressed major affective disorder patients, independent of diagnosis or overall symptomatic severity.
Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences
TLDR
The parenteral citalopram challenge test is characterized by a modest concentration-response relationship, with concentration influenced by variable PK factors, and accounting for individual differences in drug distribution may improve the power of the citalo- neuroendocrine challenge test, when used as an in vivo measure of central 5-HT function.
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.
TLDR
The Task Force on Antidepressant Medications was established to examine all aspects of therapy with antidepressant drugs and to provide mental health and other professionals with comprehensive and objective information about the different aspects of the use of antidepressants important in clinical practice.
Options when anti-depressants cannot be used in conventional ways. Clinical case and review of literature
TLDR
Various antidepressant options and management strategies practically available for psychiatrists in such situations, especially in the United States (US) and in many other countries of the world are discussed.
Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge
TLDR
It was shown that medication-specific antidepressant symptom improvements can be predicted using functional connectivity measured during acute pharmacological challenge as an easily assessable imaging marker, corroborating the advantages of the current approach of focusing on treatment-specific symptom improvements.
...
1
2
3
...

References

SHOWING 1-10 OF 31 REFERENCES
Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial.
TLDR
This trial confirmed the efficacy of citalopram 40 mg per day, and clearly supports the use of citalsopram infusion in the treatment of severely depressed, hospitalised patients.
[Citalopram (Seropram) in tablet and infusion forms in the treatment of major depression].
TLDR
Treatment with citalopram by the intravenous or oral route was most successful in anxious or inhibitory depressions, while atypical forms with hypochondriac or obsedant features responded better to infusions, and subjective preference and preference by relatives, infusions were unequivically preferred.
Acute antidepressant effect following pulse loading with intravenous and oral clomipramine.
TLDR
Pronounced early improvements in severe depressive symptoms may be achieved via loading dose regimens with clomipramine in the absence of continuous treatment, as was the amelioration in the Raskin Severity for Depression Scale and the Beck Depression Inventory scores.
Double-blind trial with oral versus intravenous clomipramine in primary depression.
TLDR
Among the patients who received the drug intravenously only CI was significantly associated with the percentage reduction of symptoms, and by pooling the two groups, CI, DMCI, and their sum all bore relationships to clinical response significant at the 0.01 level.
Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial.
TLDR
Pulse clomipramine (200 mg i.v.) is associated with dramatic reduction in depressive symptoms at day 6 after infusion, which is significantly different from the effect of placebo.
On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression--a placebo-controlled double-blind trial with doxepin.
TLDR
This randomized double-blind placebo-controlled study on doxepin is the first investigation of the effect of the switch from parenteral to oral administration on symptoms of endogenous depression and found a continuous improvement.
Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial.
TLDR
It is concluded that antidepressant treatment with citalsopram infusion followed by oral citalopram may be more efficacious than a corresponding treatment schedule with viloxazine.
Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial.
Antidepressant efficacy and tolerability of citalopram and viloxazine were compared under double-blind conditions during the first two weeks of treatment with slow drop infusion, followed by oral
Reboxetine: additional benefits to the depressed patient.
  • S. Montgomery
  • Psychology, Medicine
    Journal of psychopharmacology
  • 1997
TLDR
Reboxetine is effective in both the short- and long-term treatment of depression, and is at least as efficacious as traditional tricyclic antidepressant drugs and selective serotonin reuptake inhibitors.
A double-blind double-dummy study of citalopram comparing infusion versus oral administration.
TLDR
Slow-drop infusion with citalopram shows a similar risk/benefit relationship to oral citalipram, and pharmacological but not psychological factors which may contribute to response to slow- drop infusion are evaluated.
...
1
2
3
4
...